Nextgen Biomed is a technology pioneer in the field of topical, non steroidal treatment for psoriasis which market was estimated in 2009 at $3.5B with US as its major market.

Nextgen is seeking to revolutionize the treatment of psoriasis through its patented flagship product, a topically administered calcipotriol-nicotinamide compound, currently completed a phase 2b clinical trials.

Nextgen's technology is based on over 15 years of research by top physicians at Tel Aviv Sourasky Medical Centerᅠ.

The Company's corporate headquarter is based in Tel Aviv.

Tel Aviv Stock Exchange

About

Science

Submitting Form...

The server encountered an error.

Form received.

Product

Investors